These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Coexistence of AML1/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CML. Corm S; Biggio V; Roche-Lestienne C; Laï JL; Yakoub-Agha I; Philippe N; Nicolini FE; Facon T; Preudhomme C Leukemia; 2005 Nov; 19(11):1991-2. PubMed ID: 16151468 [No Abstract] [Full Text] [Related]
3. Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain. Stagno F; Vigneri P; Del Fabro V; Stella S; Massimino M; Berretta S; Cupri A; Consoli C; Messina L; Tirrò E; Messina A; Di Raimondo F Leuk Res; 2009 Sep; 33(9):e157-8. PubMed ID: 19406471 [No Abstract] [Full Text] [Related]
4. Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia. Otero L; Ornellas MH; Dobbin J; de Souza Fernandez T Int J Lab Hematol; 2008 Aug; 30(4):346-8. PubMed ID: 18665834 [No Abstract] [Full Text] [Related]
5. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance. Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639 [TBL] [Abstract][Full Text] [Related]
6. Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib. Chahardouli B; Zaker F; Mousavi SA; Saffari Z; Nadali F; Ostadali M; Ghadimi H; Alimoghaddam K; Ghavamzade A; Rostami S Hematology; 2013 Nov; 18(6):328-33. PubMed ID: 23676790 [TBL] [Abstract][Full Text] [Related]
7. Transgenomic's WAVE System used for the early detection of drug resistance mutations in chronic myeloid leukemia. Pharmacogenomics; 2005 Jul; 6(5):458-9. PubMed ID: 16013994 [No Abstract] [Full Text] [Related]
8. Evaluation of T315I mutation frequency in chronic myeloid leukemia patients after imatinib resistance. Chahardouli B; Zaker F; Mousavi SA; Kazemi A; Ostadali M; Nadali F; Rostami S; Alimoghaddam K; Ghavamzade A Hematology; 2013 May; 18(3):158-62. PubMed ID: 23540562 [TBL] [Abstract][Full Text] [Related]
9. Monosomy 7 in t(9;22)-negative cells during nilotinib therapy in an imatinib-resistant chronic myeloid leukemia case. Zeidan A; Kakati S; Anderson B; Barcos M; Wetzler M Cancer Genet Cytogenet; 2007 Jul; 176(2):169-71. PubMed ID: 17656263 [No Abstract] [Full Text] [Related]
10. Restoration of donor chimerism by nilotinib in a chronic myeloid leukaemia patient post mutation-associated imatinib mesylate resistance and allogeneic stem cell transplant failure. O'Connor LM; Langabeer S; McCann SR; Conneally E Bone Marrow Transplant; 2008 Dec; 42(12):833-5. PubMed ID: 18711344 [No Abstract] [Full Text] [Related]
11. Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib. Piazza RG; Magistroni V; Gasser M; Andreoni F; Galietta A; Scapozza L; Gambacorti-Passerini C Leukemia; 2005 Jan; 19(1):132-4. PubMed ID: 15510211 [No Abstract] [Full Text] [Related]
12. Switching off oncogenic signals in chronic myeloid leukaemia. Melo J; Barnes DJ Hematol J; 2004; 5 Suppl 3():S183-7. PubMed ID: 15190305 [No Abstract] [Full Text] [Related]
14. t(5;6;12) associated with resistance to imatinib mesylate in chronic myeloid leukemia. Denčić-Fekete M; Đorđević V; Storlazzi CT; Janković G; Bogdanović A; Jovanović J; Rocchi M; Todorić-Živanović B; Strnad M; Gotić M Int J Hematol; 2009 May; 89(4):508-512. PubMed ID: 19322630 [TBL] [Abstract][Full Text] [Related]
15. A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia. Roche-Lestienne C; Laï JL; Darré S; Facon T; Preudhomme C N Engl J Med; 2003 May; 348(22):2265-6. PubMed ID: 12773665 [No Abstract] [Full Text] [Related]